spironolactone has been researched along with Bile Duct Obstruction in 9 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of liver plasma membrane (LPM) fluidity in the pathogenesis of intrahepatic cholestasis in rats was assessed by comparing the effects of ethinyl estradiol, a cholestatic agent, and spironolactone on membrane fluidity and bile flow." | 3.67 | Role of liver plasma membrane fluidity in the pathogenesis of estrogen-induced cholestasis. ( Gordon, ER; Smith, DJ, 1988) |
| " Our aim was to study the hemodynamic effects of the early and chronic administration of PR and spironolactone (SPN), alone or in combination, in a model of hepatic fibrosis and sinusoidal portal hypertension induced in rats by bile duct ligation." | 1.30 | Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation. ( Calès, P; Douay, O; Gallois, Y; Le Jeune, JJ; Maïga, MY; Oberti, F; Pilette, C; Rifflet, H; Saumet, JL, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Razori, MV | 1 |
| Martín, PL | 1 |
| Maidagan, PM | 1 |
| Barosso, IR | 1 |
| Ciriaci, N | 1 |
| Andermatten, RB | 1 |
| Sánchez Pozzi, EJ | 1 |
| Basiglio, CL | 1 |
| Ruiz, ML | 1 |
| Roma, MG | 1 |
| Pass, MA | 1 |
| Pugh, MW | 1 |
| Findlay, L | 1 |
| Epping, J | 1 |
| Fuchshofen, M | 1 |
| Richter, E | 1 |
| Riabtsev, VG | 1 |
| Solomka, IaA | 1 |
| Oberti, F | 1 |
| Rifflet, H | 1 |
| Maïga, MY | 1 |
| Pilette, C | 1 |
| Gallois, Y | 1 |
| Douay, O | 1 |
| Le Jeune, JJ | 1 |
| Saumet, JL | 1 |
| Calès, P | 1 |
| Hecht, Y | 2 |
| Rigaud, D | 2 |
| Ferrier, JP | 2 |
| Celerier, M | 2 |
| Leclerc, JP | 2 |
| Potter, C | 1 |
| Willis, D | 1 |
| Sharp, HL | 1 |
| Scharzenberg, SJ | 1 |
| Smith, DJ | 1 |
| Gordon, ER | 1 |
1 trial available for spironolactone and Bile Duct Obstruction
| Article | Year |
|---|---|
[Combined treatment of mechanical jaundice].
Topics: Animals; Antioxidants; Aprotinin; Cholestasis; Combined Modality Therapy; Glucose; Hemoperfusion; Hu | 1994 |
8 other studies available for spironolactone and Bile Duct Obstruction
| Article | Year |
|---|---|
Spironolactone ameliorates lipopolysaccharide-induced cholestasis in rats by improving Mrp2 function: Role of transcriptional and post-transcriptional mechanisms.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2020 |
Studies on the mechanism of toxicity of reduced lantadene A in rats.
Topics: Adenosine Triphosphatases; Animals; Bile Canaliculi; Cholestasis; Enzyme Induction; Enzyme Inhibitor | 1981 |
[Enterohepatic circulation in liver diseases].
Topics: Animals; Barbiturates; Bile Acids and Salts; Biotransformation; Bisacodyl; Chloramphenicol; Cholesta | 1980 |
Prevention of portal hypertension by propranolol and spironolactone in rats with bile duct ligation.
Topics: Animals; Antihypertensive Agents; Cholestasis; Drug Evaluation, Preclinical; Drug Therapy, Combinati | 1997 |
[Cholestatic hepatitis and lymphatic liver congestion caused by ajmaline. Resolution of complete cholestasis with spironolactone?].
Topics: Ajmaline; Cholestasis; Female; Humans; Lymphatic Diseases; Middle Aged; Spironolactone | 1977 |
[Cholestatic hepatitis due to ajmaline. Lymphatic congestion of the liver. Recovery after spironolactone].
Topics: Ajmaline; Chemical and Drug Induced Liver Injury; Cholestasis; Female; Humans; Middle Aged; Spironol | 1978 |
Primary and secondary amenorrhea associated with spironolactone therapy in chronic liver disease.
Topics: Adolescent; Adult; Amenorrhea; Cholestasis; Chronic Disease; Female; Humans; Hypertension, Portal; H | 1992 |
Role of liver plasma membrane fluidity in the pathogenesis of estrogen-induced cholestasis.
Topics: Animals; Bile; Cholestasis; Ethinyl Estradiol; Fluorescence Polarization; Liver; Male; Membrane Flui | 1988 |